Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

Cancer

Volumn 120, Issue 11, 2014, Pages 1695-1701

  Ackerman, Allison ^a   Klein, Oliver ^b   McDermott, David F ^a   Wang, Wei ^c   Ibrahim, Nageatte ^d   Lawrence, Donald P ^e   Gunturi, Anasuya ^a   Flaherty, Keith T ^e   Hodi, F Stephen ^d   Kefford, Richard ^b,f,g,h   Menzies, Alexander M ^g,h   Atkins, Michael B ⁱ   Long, Georgina V ^f,g,h   Sullivan, Ryan J ^e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b WESTMEAD HOSPITAL   (Australia)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f WESTMEAD HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h MELANOMA INSTITUTE AUSTRALIA   (Australia)

ⁱ GEORGETOWN UNIVERSITY   (United States)

Author keywords

BRAF; ipilimumab; melanoma; sequencing; vemurafenib

Indexed keywords

DABRAFENIB; IPILIMUMAB; TRAMETINIB; VEMURAFENIB;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BRAF; IPILIMUMAB; MELANOMA; SEQUENCING; VEMURAFENIB;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84901340078     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28620     Document Type: Conference Paper

References (18)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364: 2517-2526.
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
4. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380: 358-365.
5. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367: 107-114.
6. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med. 2012; 367: 1694-1703.
7. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N,. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med. 2012; 10: 107.
8. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17: 2105-2116.
9. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17: 4550-4557.
10. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455-2465.
11. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-2454.
12. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369: 134-144.
13. Hamid O, Sosman J, Lawrence D, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM) [Abstract]. J Clin Oncol. 2013; 31 (suppl): abstract 9010.
14. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366: 707-714.
15. Weber JS, Kahler KC, Hauschild A,. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30: 2691-2697.
16. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19: 1225-1231.
17. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012; 18: 1386-1394.
18. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13: 1087-1095.